Company Overview - The company operates a leading online insurance marketplace, connecting consumers and insurance providers[10] - The company's platform leverages over 4 billion consumer data points[15,22] - The company has diversified distribution model with approximately 60 carriers and 6,000 third-party agents[15] Market Opportunity - The total P&C distribution and advertising spend market is estimated at $117 billion annually[10,17] - Digital advertising spend within the P&C insurance market is $7 billion[17] - The company estimates its share of the P&C distribution and advertising spend market is less than 1%[18] - The estimated digital advertising spend growth in the U S P&C insurance market is approximately 15% annually from 2023 to 2026[18] Financial Performance - The company's Q2 2025 revenue increased by 34% year-over-year to $156 6 million[32,43] - Auto insurance revenue in Q2 2025 grew by 36% year-over-year to $139 6 million[43] - Home/Renters insurance revenue in Q2 2025 increased by 23% year-over-year to $17 0 million[43] - Adjusted EBITDA for Q2 2025 was $22 0 million, representing a 70% increase year-over-year[32]

Financial Performance & Guidance - Q2 2025 total revenues reached $2.96 billion, compared to $2.65 billion in Q2 2024[48] - The company reiterated its 2025 total revenue guidance of $11.85-$12.0 billion[7] - Non-GAAP operating income for Q2 2025 was $1.33 billion, with a 45% operating margin[48] - Non-GAAP net income for Q2 2025 was $1.17 billion, or $4.52 per share diluted[48] - The company expects combined non-GAAP R&D, AIPR&D, and SG&A expenses to be $4.9-$5.0 billion for 2025[49] Key Product Updates - ALYFTREK generated $157 million in revenue in Q2 2025 and is approved for ages 6+ in the U S, U K, EU & Canada[33,48] - CASGEVY generated $30 million in revenue in Q2 2025, with 29 total patients infused since launch[40,48] - JOURNAVX generated $12 million in revenue in Q2 2025, with >110,000 prescriptions successfully filled as of mid-July[47,48] Pipeline Development - The company plans global regulatory submissions for Zimislecel (T1D) in 2026, targeting an initial launch to ~60,000 severe T1D patients[7,12] - Povetacicept (IgAN) Phase 3 interim analysis cohort is fully enrolled, with potential U S filing for accelerated approval in H1 2026[7,19] - VX-407 (ADPKD) Phase 2 proof-of-concept study is set to begin in Q3 2025, targeting up to ~30,000 patients with a subset of variants in the PKD1 gene[7,30]

Financial Performance & Revenue - Q2 2025 revenue breakdown: Projects contribute $358.1 million, Energy & incentive revenue from owned energy assets plus recurring O&M from projects is $90.9 million, and other sources including services, software and integrated PV account for $23.3 million[5] - Year-to-date 2025, total revenue is $825 million, with projects accounting for 74%, assets for 15%, O&M for 6%, and other sources for 5%[7] - Year-to-date 2025, adjusted EBITDA is $97 million, with assets contributing 66%, projects 26%, O&M 5%, and other sources 3%[7] - Ameresco's total debt is $1.82 billion, of which $1.50 billion is energy asset debt[14, 15] - Of the energy asset debt, $0.99 billion is associated with operating energy assets, and $0.51 billion is associated with energy assets in development & construction[16] Energy Assets & Backlog - Operating energy assets total 749 MWe, comprising 56% solar (421 MW), 22% battery (166 MW), 11% non-RNG biogas (83 MWe), 9% RNG biogas (70 MWe), and 1% other[10, 11] - Energy assets in development & construction total 615 MWe, with 40% battery, 23% firm generation, 22% solar, and 15% biogas[11] - The company has a diversified total project backlog of $5.1 billion as of June 30, 2025, with $2.4 billion in awarded project backlog and $2.7 billion in contracted project backlog[21, 23] - The operating energy assets have a $1.3 billion backlog with a 15.1 year weighted average PPA remaining, plus an additional estimated revenue from market price RNG of $1.45 billion[21] Sustainability Impact - Since 2010, Ameresco's renewable energy assets & customer projects delivered a carbon emission reduction equivalent to over 125 million metric tons of CO2[30]

Financial Performance - Total Revenues for Q2 2025 reached $825 million, a 16% year-over-year increase[17, 22] - VOXZOGO revenue in Q2 2025 was $221 million, representing a 20% year-over-year growth[17, 22] - Enzyme Therapies revenue in Q2 2025 was $555 million, a 15% year-over-year increase[17, 22] - Non-GAAP Operating Margin for Q2 2025 was 39.9%, an increase of 8.7 percentage points year-over-year[25] - Non-GAAP Diluted EPS for Q2 2025 was $1.44, a 50% increase year-over-year[17, 30] - Operating Cash Flow for Q2 2025 was $185 million, a 55% increase year-over-year[30] - The company increased FY'25 Total Revenues guidance to $3,125 million to $3,200 million[24, 34] - The company increased FY'25 Non-GAAP Diluted EPS guidance to $4.40 to $4.55[33, 34] Product and Pipeline Updates - VOXZOGO's contribution to full-year 2025 Total Revenues is expected to be in the range of $900 million to $935 million[24, 34] - BMN 333 Phase 1 data showed >3x AUC PK free CNP levels vs other long-acting CNP[17, 45] - Submissions for PALYNZIQ age eligibility expansion for adolescents (12-17 y/o) in the U S and Europe are planned for 2H 2025[3, 48, 51, 56]

Financial Performance - Revuforj net revenue in 2Q25 reached $28.6 million, representing a 43% quarter-over-quarter growth[6] - Niktimvo net revenue reported by Incyte in 2Q25 was $36.2 million, a substantial increase from $13.6 million in the first two months of Q1 launch[9] - Syndax reported $9.4 million in collaboration revenue from Niktimvo in 2Q25, achieving profitability in the first full quarter[9] - Syndax holds a strong financial position with $518 million in cash and equivalents as of June 30, 2025[28] Product Pipeline and Market Opportunity - Syndax estimates a $5B+ Total Addressable Market (TAM) for Revuforj and another $5B+ TAM for Niktimvo, indicating a $10B+ market opportunity across R/R and frontline indications[4, 30] - The initial Niktimvo indication represents a $2B U S market opportunity, with potential for label and geographic expansion leading to a $5B+ TAM[19, 20] - Approximately 33% of KMT2A patients are estimated to have proceeded to hematopoietic stem cell transplantation (HSCT) following Revuforj treatment[6, 12] Clinical Data and Development - Phase 2 Relapsed/Refractory (R/R) mNPM1 AML data for Revumenib showed a 26% (20/77) CR+CRh rate and a 48% (37/77) Overall Response Rate (ORR)[26] - Phase 1 R/R NUP98r AML data for Revumenib showed a 60% (3/5) ORR[26] - Over 80% of bone marrow transplant centers have ordered Niktimvo[18]

Financial Performance - SI-BONE achieved 21.7% worldwide revenue growth, reaching $48.6 million in the second quarter of 2025[8] - U S revenue grew by 22.8% to $46.4 million in the second quarter of 2025[8] - The company reported a gross margin of 79.8%, an improvement of 80 basis points[8] - Adjusted EBITDA was positive at $1.0 million, marking the third consecutive quarter of positive AEBITDA[8, 16] - The company generated $1.1 million in net cash[8] - SI-BONE has $145.5 million in cash and equivalents[17] Market and Physician Engagement - U S active physicians increased by 25%[8, 10] - The company has experienced 18 consecutive quarters of double-digit U S active physician growth[13] Guidance and Future Opportunity - SI-BONE updated its 2025 worldwide revenue guidance to $195 - $198 million, implying a growth of approximately 17%-18% year-over-year[21] - The company estimates a total U S addressable market opportunity of over $3.5 billion[23, 31] - iFuse TORQ TNT received NTAP with payment of $4,136[8, 59]

Financial Performance - Denny's system-wide same-restaurant sales increased by 3.7% YTD in 2025[4] - Keke's Q2 2025 LTM system AUV sales reached $1.9 million[4] - Denny's Q2 2025 domestic average weekly sales were approximately $38,400[14] - Denny's allocated over $713 million towards share repurchases since the program began in late 2010[49] - Denny's has approximately $88 million remaining under existing repurchase authorization[49] Sales Mix and Trends - Denny's off-premises sales mix was 16% YTD in 2025[4] - Keke's off-premises sales were approximately 16% during Q2 2025[12] - Over 65% of Denny's overall domestic Q2 2025 sales were during the breakfast and lunch dayparts[16] Restaurant Footprint and Franchise - Denny's has a total of 1,484 restaurants[4] - Denny's has 1,321 restaurants in the U S[23] - Denny's international presence includes 163 restaurants in 14 countries and U S Territories[23] - Keke's operates 74 cafes in seven different states[43]

Financial Performance - Net sales reached $1.388 billion, a 32% increase year-over-year and a 25% sequential increase[12, 14] - Adjusted EBITDA was $338 million, a 79% year-over-year increase and a 41% sequential increase[12, 14] - RemainCo (ANS and Ruckus) net sales were $513 million, a 58% increase year-over-year and a 32% sequential increase[12, 14] - RemainCo Adjusted EBITDA was $127 million, a 326% increase year-over-year and a 101% sequential increase[9, 12] - The company is revising its 2025 Adjusted EBITDA guideposts up to between $1.15 billion and $1.20 billion, with RemainCo expected to contribute between $325 million and $350 million[11] Strategic Initiatives - The company entered into a definitive agreement to sell its CCS business to Amphenol for $10.5 billion in cash, expected to close in the first half of 2026[9] - The company anticipates approximately $500 million in fees and taxes related to the CCS sale[9] - The company intends to use the proceeds from the CCS sale to pay off debt and preferred equity and distribute excess cash, with minimal leverage on RemainCo[9] Liquidity and Debt - The company ended the quarter with over $991 million in available liquidity, including $571 million in cash[26] - Net leverage as of June 30, 2025, was 6.6x based on pro forma Adjusted EBITDA from continuing operations of approximately $1.025 billion[24, 25] Segment Performance - Connectivity and Cable Solutions (CCS) net sales increased by 20% year-over-year, driven by Cloud and Hyperscale datacenter growth, with EBITDA margin remaining strong at 24.1%[16] - Access Network Solutions (ANS) net sales increased by 65% year-over-year, with Adjusted EBITDA increasing by 132% due to DOCSIS 4.0 product revenue and increased license sales[16] - Ruckus net sales increased by 47% year-over-year, driven by a return to stabilized buying patterns in the channel, with Adjusted EBITDA increasing by $51 million[16]

The Semler Vision: Monetary and Medical Freedom Bitcoin Backed by Early Detection of Chronic Diseases August 4, 2025 Forward-Looking Statements . This presentation includes strbements that are, or may be deemed, "forward-looking statements." In some cases, hese forward-looling statements can be identified by the us looking terminabogy, including the terms "believe," "estimate," "anticipate," "expect," "plan," "intend," "may," "could," "might" "will," "should," or, in ecch case, their variations thereon or c ...

Financial Performance & Growth - Q2 2025 total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased by 33% year-over-year compared to Q2 2024[14, 61] - Gross Margin for Q2 2025 was 77%, while Adjusted Gross Margin reached 80%, slightly lower than the 81% and 83% respectively in the same period of 2024[14] - Net cash provided by operations in Q2 2025 was $20.8 million, a decrease from $24.0 million in Q2 2024[14] - As of June 30, 2025, the company's cash, cash equivalents, and marketable investment securities totaled $275.9 million[14] - Net income for Q2 2025 was $4.5 million, and Adjusted EBITDA was $10.4 million[14] Strategic Initiatives - The company aims to achieve operating cash flow positivity by the end of 2025[4, 60] - The company closed its acquisition of Previse, a gastrointestinal health company, focusing on chronic acid reflux related diseases, including esophageal cancer[14] - The company entered into a collaboration and license agreement with SciBase to develop diagnostic tests for dermatologic diseases[14] Market Penetration & Clinical Utility - DecisionDx-Melanoma clinical use is associated with improved patient survival, with a 29% lower 3-year melanoma-specific mortality and a 17% lower 3-year overall mortality in tested patients compared to untested patients[38] - DecisionDx-SCC Class results predict an SCC patient's individual metastatic risk and individual benefit of ART[44] - TissueCypher is the strongest independent predictor of progression to HGD or EAC in Barrett's esophagus patients, detecting 62% of progressors[51, 52]